Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945814 | 0.86 | PIK3CD (0.75) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL6322590 | 0.84 | PIK3CD (0.57) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL27725234 | 0.83 | PIK3CD (0.66) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL2193011 | 0.82 | PIK3CD (0.70) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL29712113 | 0.82 | PIK3CD (0.70) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL6322388 | 0.82 | ASH1L (0.59) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL13115632 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3CBMAPK14ASH1LPIK3CG | |
| SCHEMBL6321966 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3CBASH1LPIK3CGCSNK2B | |
| SCHEMBL6322061 | 0.81 | PIK3CD (0.64) | PIK3CDNR4A2PIK3CBMAPK14ASH1L | |
| SCHEMBL27504678 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3CBMAPK14ASH1LPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | claimed |
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | PIK3CD 365/4885NR4A2 904/4885PIK3CB 275/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | PIK3CD 365/4885NR4A2 904/4885PIK3CB 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.